3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance

Kinan Alhallak, Pilar de la Puente, Amanda Jeske, Jennifer Sun, Barbara Muz, Michael P. Rettig, Ilyas Sahin, Ellen L. Weisberg, James D. Griffin, John L. Reagan, John F. DiPersio, Abdel Kareem Azab

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL) are hematological malignancies that remain incurable despite novel treatments. In order to improve current treatments and clinical efficacy, there remains a need for more complex in vitro models that mimic the intricate human leukemic microenvironment. This study aimed to use 3D tissue engineered plasma cultures (3DTEPC) derived from CML, AML and CLL patients to promote proliferation of leukemic cells for use as a drug screening tool for treatment. 3DTEPC supported the growth of primary CML, AML and CLL cells and also induced significantly more drug resistance in CML, AML and CLL cell lines compared to 2D. The 3DTEPC created a more physiologically relevant environment for leukemia cell proliferation, provided a reliable model for growing leukemia patient samples, and serves as a relevant tool for drug screening and personalized medicine.

Original languageEnglish
Pages (from-to)2457-2465
Number of pages9
JournalLeukemia and Lymphoma
Issue number10
StatePublished - 2021


  • Leukemia
  • drug resistance
  • patient-derived 3D culture


Dive into the research topics of '3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance'. Together they form a unique fingerprint.

Cite this